Clinical Trial Update: A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, efficacy, and pharmacokinetics of tildacerfont in children aged 2-17 with congenital adrenal hyperplasia (21-hydroxylase defici…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• 21-hydroxylase Deficiency
• Congenital Adrenal Hyperplasia

Drugs mentioned

• Tildacerfont (tildacerfont)

Snippet

Sponsor: Spruce Biosciences | Conditions: Congenital Adrenal Hyperplasia, 21-OHD | Phase 2 | Status: TERMINATED | Results posted: 2025-12-24